KalVista Pharma

Chiesi has completed the acquisition of KalVista, acquiring all outstanding shares for $27.00 per share in cash after approximately 77.8% of the shares were tendered. KalVista becomes a wholly owned subsidiary and is valued at $1.44 billion; trading of the common shares was suspended on Nasdaq. Chiesi acquires the oral HAE treatment EKTERLY (Sebetralstat) and is integrating KalVista into its rare diseases unit, while approvals in additional markets and pediatric studies are underway. » Más en de.investing.com

Christopher Yea exercised 33,800 options and immediately sold the resulting KalVista shares for about $905,000 at a weighted average price of $26.78 on May 27, 2026, leaving him with 229,918 shares valued at roughly $6.16 million. The sale is Yea's second open-market disposal and did not increase his long-term holdings since the shares were sourced from vested options. The report notes a pending buyout offer from Chiesi Group at $27 per share expected to close in Q3 2026 and summarizes KalVista's commercial focus on oral plasma kallikrein inhibitors and recent Ekterly sales. » Más en finance.yahoo.com

KalVista’s stock rose to a 52-week high of $26.85, driven by the announcement of an acquisition by the Chiesi Group for about $1.9 billion. Chiesi is offering $27.00 per share, a 36% premium to the volume-weighted 30-day average; the acquisition was unanimously approved by both boards and is expected to close in Q3 2026. After the news, analysts adjusted their ratings, mostly downgrading the stock from “Buy” to “Neutral/Hold” and setting the price target at the offer price. » Más en de.investing.com